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ABSTRACT The microbiota-gut-brain axis is a bidirectional communication system
that is poorly understood. Alzheimer’s disease (AD), the most common cause of de-
mentia, has long been associated with bacterial infections and inﬂammation-causing
immunosenescence. Recent studies examining the intestinal microbiota of AD pa-
tients revealed that their microbiome differs from that of subjects without dementia.
In this work, we prospectively enrolled 108 nursing home elders and followed each
for up to 5 months, collecting longitudinal stool samples from which we performed
metagenomic sequencing and in vitro T84 intestinal epithelial cell functional assays
for P-glycoprotein (P-gp) expression, a critical mediator of intestinal homeostasis.
Our analysis identiﬁed clinical parameters as well as numerous microbial taxa and
functional genes that act as predictors of AD dementia in comparison to elders
without dementia or with other dementia types. We further demonstrate that stool
samples from elders with AD can induce lower P-gp expression levels in vitro those
samples from elders without dementia or with other dementia types. We also paired
functional studies with machine learning approaches to identify bacterial species dif-
ferentiating the microbiome of AD elders from that of elders without dementia,
which in turn are accurate predictors of the loss of dysregulation of the P-gp path-
way. We observed that the microbiome of AD elders shows a lower proportion and
prevalence of bacteria with the potential to synthesize butyrate, as well as higher abun-
dances of taxa that are known to cause proinﬂammatory states. Therefore, a potential
nexus between the intestinal microbiome and AD is the modulation of intestinal ho-
meostasis by increases in inﬂammatory, and decreases in anti-inﬂammatory, microbial
metabolism.
IMPORTANCE Studies of the intestinal microbiome and AD have demonstrated as-
sociations with microbiome composition at the genus level among matched cohorts.
We move this body of literature forward by more deeply investigating microbiome
composition via metagenomics and by comparing AD patients against those without
dementia and with other dementia types. We also exploit machine learning ap-
proaches that combine both metagenomic and clinical data. Finally, our functional
studies using stool samples from elders demonstrate how the c microbiome of AD
elders can affect intestinal health via dysregulation of the P-glycoprotein pathway.
P-glycoprotein dysregulation contributes directly to inﬂammatory disorders of the in-
testine. Since AD has been long thought to be linked to chronic bacterial infections
as a possible etiology, our ﬁndings therefore ﬁll a gap in knowledge in the ﬁeld of
AD research by identifying a nexus between the microbiome, loss of intestinal ho-
meostasis, and inﬂammation that may underlie this neurodegenerative disorder.
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The concept of the “gut-brain axis,” which originated from behavioral studies inmicrobiome-reconstituted mice, has advanced current research supporting the
concept that the microbiome may be responsible for some of the most devastating
neurodegenerative disorders, including Alzheimer’s disease (AD) (1). This is further
underscored by observations linking AD pathogenesis to chronic bacterial infections as
a possible etiology (2, 3). Recent studies have investigated this connection, identifying
signiﬁcant changes in the proportion of certain microbiome taxa in AD patients (4, 5),
and have correlated microbiota composition with levels of AD biomarkers in cerebro-
spinal ﬂuid (4). Moreover, increased proportions of proinﬂammatory and reduced
proportions of anti-inﬂammatory bacteria in the intestine are associated with systemic
inﬂammatory states in patients with cognitive impairment and brain amyloidosis (6).
Thus, a current tenet supports the idea that AD pathogenesis is not only closely related
to the imbalance of the gut microbiome but may also originate in the gut (3, 7, 8).
The healthy human intestine involves a dynamic balance between the host immune
response, the large population of resident bacteria, and the thin epithelial layer that
separates them. Dysregulation of this balance can have serious consequences that may
drive a variety of pathological conditions. The intestinal epithelia therefore serve as a
physical barrier to microbial penetration and provide a sentinel system to warn immune
cells of pathogen exposure or injury. This places them in an ideal position to regulate
the balance between pro- and anti-inﬂammatory states. Previously, we characterized a
balanced system at the intestinal mucosal surface in which eukaryotic ABC transporters
and their efﬂux products play a fundamental role in immunomodulation (9, 10). This
dynamic balance operates between homeostatic pathways that suppress immune
responses to commensal bacteria (the P-glycoprotein [P-gp]/endocannabinoid axis)
and inﬂammatory pathways that activate responses to pathogens or aberrant signals
(multidrug-resistant protein 2 [MRP2]/hepoxilin A3) and can be unhinged by a dysbiotic
microbiome (9). Dysregulation of this critical balance contributes directly to inﬂamma-
tory disorders of the intestine. To understand more deeply how speciﬁc intestinal
bacterial taxa associate with AD and the extent to which such taxa alter the balance of
intestinal epithelial homeostasis, we explored the microbiome composition of nursing
home (NH) elders with AD, no dementia, or other dementia types.
RESULTS
Elders with dementia have increased frailty and malnutrition scores. One
hundred eight NH elders were prospectively enrolled and followed for up to 5 months.
Longitudinal stool samples, taken one time each month for a total of 300 samples, were
collected. Of the 108 elders, 51 (47.2%) had no dementia, while 24 elders (22.2%) had
AD and 33 elders (30.6%) had other dementia types. Of note, elders who were exposed
to antimicrobials, had changes in medications, or required hospitalization during the
study period were excluded from this study. A greater proportion of elders with AD or
other dementia types were taking atypical antipsychotics and presented with higher
malnutrition and frailty scores than did those with no dementia (Table 1). This is
consistent with prior studies documenting that frailty and malnutrition are related to
dementia (11–14). Strong associations have been shown among both frail and prefrail
elders with a poorer cognitive status (15), and frailty has been linked to the level of AD
pathology found on postmortem examination (12). Malnutrition is a common problem
among NH elders, with upwards of 33% suffering from this condition (16). Among AD
elders, the most malnourished display decreased cognitive and functional capacities
(11).
We also noted a decreased prevalence of proton pump inhibitor (PPI) use among
both dementia types. Besides atypical antipsychotics, other medications known to
affect the microbiome did not differ among the three groups, including the proportion
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of elders with polypharmacy. Additionally, we did not note any signiﬁcant difference in
age, sex, or medical histories among these groups. The majority of elders with Alzhei-
mer’s type dementia had moderate/severe symptoms deﬁned by clinical dementia
rating (CDR) scores of 2 to 3 (mean CDR score, 2.12; standard deviation [SD], 0.33), while
elders with other dementia types had less severe symptoms (mean CDR score, 1.88; SD,
0.95; P 0.026).
Microbiome composition differs by dementia type. We evaluated the beta diversity
of the intestinal microbiome between elders without dementia, with AD, and with other
dementia types, using Jaccard distances as a measure of species-level community
dissimilarity visualized using t-distributed stochastic neighbor embedding (tSNE)
(Fig. 1). Elders with AD cluster away from those without dementia. Individuals with
other dementia diagnoses are clustered with both cohorts. Moreover, Jaccard distances
between samples from individuals with AD were more similar than those from indi-
viduals with no dementia or other dementia types (permutational multivariate analysis
of variance [PERMANOVA], Jaccard distance P 0.001).
Differences in the relative abundances of bacterial genera for elders with no
dementia versus AD and other dementia types were characterized via generalized
linear mixed models. Speciﬁcally, after using Kraken to map reads to a k-mer database
of bacterial NCBI genomes (17) and estimating the relative abundances of each species
with Bracken (18), we determined the relative abundances at the genus level. Beta-
regression mixed-effect modeling was then used to predict the proportion of each
genus as a function of the ﬁxed effects of dementia status, age, malnutrition, frailty, and
medications, including those we previously showed to signiﬁcantly affect microbiome
composition (19–21) (Table 1) and considering the individual elder as random effect.
After adjusting for these clinical covariates, several genera were found to be signiﬁ-
cantly associated with AD (Fig. 2). When setting no dementia as the baseline, increased
proportions of Bacteroides spp. (P 0.031), Alistipes spp. (P 0.001), Odoribacter spp.
(P 0.001), and Barnesiella spp. (P 0.023) and decreased proportions of Lachnoclos-
tridium spp. (P 0.048) were present in AD elders, while increased proportions of
Odoribacter spp. (P 0.025) and Barnesiella spp. (P 0.024) and decreased propor-
tions of Eubacterium spp. (P 0.001), Roseburia spp. (P 0.034), Lachnoclostridium
spp. (P 0.048), and Collinsella spp. (P 0.001) were seen in elders with other
dementia types. Other studies, based on 16S rRNA sequencing, have found similar
TABLE 1 Clinical data by dementia type
Patient characteristica
Data by dementia type
P valueNo dementia Alzheimer’s disease Other dementia
Age (mean [SD]) (yr) 83.0 (10.2) 84.7 (8.1) 87.9 (7.9) 0.06
Age category (mean [SD])b 2.3 (1.0) 2.5 (0.8) 2.8 (0.8) 0.41
Male 8 (15.7) 4 (16.7) 6 (18.2) 0.96
Diabetic 11 (21.6) 5 (20.8) 9 (27.3) 0.80
Immunosuppressed 3 (5.9) 1 (4.2) 0 (0.0) 0.38
Malignancy 6 (11.8) 2 (8.3) 3 (9.1) 0.87
CKD 15 (29.4) 9 (49.5) 10 (30.3) 0.77
CCI score (mean [SD]) 1.65 (1.7) 1.38 (1.2) 1.58 (1.6) 0.79
Medications
PPI 16 (31.4) 1 (4.2) 6 (18.2) 0.024
Statin 11 (21.6) 4 (16.7) 8 (24.2) 0.79
Antipsychotic 0 (0.0) 4 (16.7) 2 (6.1) 0.013
Polypharmacy 34 (66.7) 14 (58.3) 22 (66.7) 0.75
Clinical scores
Malnutrition (mean [SD]) 1.7 (0.7) 2.3 (0.6) 2.3 (0.6) 0.0001
Frailty (mean [SD]) 2.9 (1.0) 3.4 (0.7) 3.7 (0.6) 0.003
aData are presented as the number (%), unless otherwise speciﬁed. CKD, chronic kidney disease; CCI,
Charlson comorbidity index.
bThe age categories are as follows: category 1, 65 to 74 years; category 2, 75 to 84 years; category 3, 85 to 94
years; and category 4, 95 years.
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associations and also reported increases in Bacteroides spp. and Alistipes spp. (4), as well
as decreased proportions of Roseburia spp. (5) in AD patients, consistent with what we
report above. Differences in the other genera reported here are likely due to different
methodologies applied, as we used shotgun metagenomics and mixed modeling rather
than 16S rRNA and subject matching based only on age and sex. We have previously
reported the importance of frailty and malnutrition on microbiome composition (19).
There is also a growing awareness of medication effects on the intestinal microbiota
FIG 1 Microbiome diversity differs between Alzheimer’s disease elders and those with no dementia or
other types of dementia. Stool samples from elders were sequenced via shotgun metagenomics. Samples
were proﬁled for microbial species relative abundances by mapping reads to a NCBI bacterial genomes
k-mer database with Kraken and by reconstructing the resulting relative abundance proﬁle at the species
levels with Bracken. Beta diversity was explored using Jaccard distances by t-distributed stochastic
neighbor embedding (tSNE) for a measure of community species dissimilarity among samples collected
from individuals without dementia (blue triangles), with Alzheimer’s disease (red circles), and with other
dementia types (yellow squares). Each group is displayed with ellipses with a 95% conﬁdence interval.
FIG 2 After adjusting for relative clinical covariates, microbiome composition differs at the genus level among elders with Alzheimer’s disease, no dementia,
and other dementia types. We performed generalized mixed-effect modeling regression to predict genus-level proportions as a function of age, malnutrition,
frailty, medications, and dementia state (no/other/AD). Patient ID was used as random effect to account for the repeated nature of our samples. Genera with
greater than 0.1% mean relative abundance were signiﬁcantly associated with Alzheimer’s disease (AD) or other dementia types (Other) in comparison to elders
without dementia (NO). Only genera with a P value of 0.05 are presented, with relative abundance on the y axis.
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(21, 22). We believe that including these key clinical variables is important when
analyzing microbiome associations with disease outcomes.
Accurate classiﬁcation of AD individuals compared to those without dementia
using metagenomic and clinical measures. To identify taxonomic and clinical cova-
riates that optimally differentiate AD elders from those with no dementia or other
dementia types, two separate random forest classiﬁcation algorithms were imple-
mented (23, 24). The matrix of predictors included in each of the models consisted of
species level, taxonomic relative abundances, and clinical measures. To account for the
time dependence of our data, we performed 30 trials of the random forest classiﬁcation
algorithm, in which we randomly selected one sample per individual. A leave-one-out
cross-validation approach was used, in which we trained the forest in n  1 individuals
and used the model to predict the membership of the left-out individual. The analysis
was repeated 100 times using different random seeds. We averaged out-of-bag (OOB)
error across the 30 100 trials and ranked predictors (taxa and clinical factors) with
respect to their importance in classiﬁcation according to their respective mean de-
creased accuracy distribution.
Our analysis identiﬁed two clinical parameters, increasing frailty and malnutrition, as
predictors of AD dementia, as well as numerous microbial taxa with known association
to inﬂammatory and neurological disorders (Fig. 3, and summarized in Table S1 in the
supplemental material). Speciﬁcally, AD elders were characterized by lower proportions
of key butyrate-producing species, such as members of the Butyrivibrio (B. hungatei and
B. proteoclasticus) and Eubacterium (E. eligens, E. hallii, and E. rectale) genera, as well as
Clostridium sp. strain SY8519, Roseburia hominis, and Faecalibacterium prausnitzii. Met-
agenomic analysis of metabolic pathways also indicates a similar pattern, in that elders
without dementia have an increase in butyrate-coding genes from four separate
butyrate biosynthetic pathways present in all bacteria in comparison to AD elders
(Fig. S1).
Remarkably, AD elders had increased proportions of speciﬁc bacterial species that
have associations with neurological disorders (including AD). These include Odoribacter
splanchnicus, a bacterial species with genes that have been associated with the
Alzheimer’s pathway (25). Other bacterial species identiﬁed as predictors of AD demen-
tia include taxa known to cause inﬂammatory states, such as Bacteroides vulgatus
(Fig. 3). This species has recently been identiﬁed as inﬂuencing neuroinﬂammatory
signaling (26) and also has been associated with autism (27) and autoimmune diabetes
(28, 29). AD elders were also depleted in Adlercreutzia equolifaciens, an equol-producing
bacterium, which has beneﬁcial effects in reducing experimental cutaneous inﬂamma-
tion in mice (30, 31) and the loss of which has been associated with the neurodegen-
erative disorder multiple sclerosis (32). Human pathogens Klebsiella pneumoniae, Bac-
teroides fragilis, and Eggerthella lenta were also shown to be increased in relative
abundance in our AD elders (Fig. 3).
Accurate classiﬁcation of AD versus other dementia types using only meta-
genomic measures. We applied random forest classiﬁcation to discriminate AD elders
from elders with other types of dementia (Fig. 4). Interestingly, no clinical variables
emerged in the top 30 discriminating variables from this random forest analysis.
Analogous to the AD versus no-dementia class comparison (Fig. 3), AD elders associ-
ated with enriched proportions of previously described dysbiotic bacteria, such as O.
splanchnicus, E. lenta, and K. pneumoniae, and with decreased proportions of butyrate-
producing B. hungatei, Blautia hansenii, E. eligens, R. hominis, Ruminococcus bicirculans,
and F. prausnitzii (Fig. 4 and summarized in Table S2). Similarly, Bacteroides dorei,
another bacterium with known association to autoimmune conditions and type 1
diabetes (29), is enriched in AD compared to both no-dementia and to other dementia
type elders (Fig. 3C and 4C). Surprisingly, compared to elders with AD, elders with other
dementia types had higher proportions of some opportunistic pathogens, including
Ralstonia pickettii and Ralstonia mannitolilytica (33, 34), as well as B. fragilis, the most
commonly isolated anaerobic pathogen (35). Our analysis also identiﬁed other species
from genera that have been recently reported to have lower (Biﬁdobacterium biﬁdum)
Alzheimer’s Microbiome and P-gp Pathway Dysregulation ®
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FIG 3 Microbiome species composition, combined with frailty and malnutrition, accurately classify individuals as having Alzheimer’s disease versus no
dementia. Random forest classiﬁcation was performed according to Alzheimer’s disease versus no dementia (AD versus NO) by selecting at random one sample
per individual (30 trials per run), from 100 starting random seeds, and building 3,000 decision trees per trial. (A) Out-of-bag (OOB) prediction error as a function
of the number of decision trees run for elders without dementia (NO, blue) or with Alzheimer’s disease (AD, red). (B) Ranking of forest predictors based on
average variable importance (e.g., mean decreased accuracy) across the 30 100 random trials. The top 30 important features discriminating the AD and NO
dementia are reported. (C) Relative abundances for each species selected or scoring number for frailty and malnutrition clinical variables are reported with mean
(thick bar) and up to minimum and maximum values for elders without dementia (NO, blue) or with Alzheimer’s disease (AD, red). In panel B, species are ordered
based on importance.
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FIG 4 Microbiome species composition accurately classify individuals as having Alzheimer’s disease versus other dementia types. Random forest classiﬁcation
was also performed according to Alzheimer’s disease versus no other dementia diagnosis (AD versus other) by selecting at random one sample per individual
(30 trials per run), from 100 starting random seeds, and building 3,000 decision trees per trial. (A) Out-of-bag (OOB) prediction error as a function of the number
of decision trees run for elders without dementia (other, yellow) or with Alzheimer’s disease (AD, red). (B) Ranking of forest predictors based on average variable
importance (e.g., mean decreased accuracy) across the 30 100 random trials. The top 30 important features discriminating AD and other dementia are
reported. (C) Relative abundances for each species selected by the model are reported with mean (thick bar) and up to minimum and maximum values (dots)
for elders with other dementia types (other, yellow) or with Alzheimer’s disease (AD, red). In panel B, species are ordered based on importance.
Alzheimer’s Microbiome and P-gp Pathway Dysregulation ®
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or higher (Prevotella denticola and Akkermansia muciniphila) proportions among AD
patients (5).
Microbiome of AD elders modulates intestinal homeostasis through P-glycoprotein
regulation. Our observed taxonomy associations in elders with AD may represent a
proinﬂammatory microbiome that contributes to the inﬂammation-causing immunose-
nescence and is thought to be associated with the development of AD. To examine the
notion that the microbiota from AD elders alone can differentially promote an inﬂam-
matory state, perhaps altering intestinal epithelial homeostasis, we tested stool samples
for their ability to modulate the P-gp/endocannabinoid (homeostasis)-MRP2/HXA3
(inﬂammatory) axis (9, 36). For this analysis, polarized T84 intestinal epithelial cell
monolayers were incubated in the presence of stool supernatants, followed by quan-
tiﬁcation of P-gp and MRP2 protein expression (36, 37). Stool supernatants from AD
elders induced a signiﬁcantly lower expression of functional P-gp than did supernatants
from elders with no dementia or other dementia types (Fig. 5A, P 0.017). MRP2
expression was higher in response to stool supernatants from AD elders, but this
observation did not reach signiﬁcance (Fig. 5B).
Taxonomic predictors of AD can also accurately predict in vitro P-gp expres-
sion.We next sought to determine if taxonomic predictors of AD could also predict the
P-gp response. Applying an approach we have used to decouple the effect of a
consortium of gut bacteria on an anti-inﬂammatory phenotype (38), we built random
forest regression models in which we predicted the experimentally measured P-gp
expression as a function of the relative bacterial abundances. Our model selected only
the top 30 important species for AD prediction as covariates; the other model consid-
FIG 5 Intestinal microbiome of elders with Alzheimer’s disease induce signiﬁcantly lower P-glycoprotein
expression from intestinal epithelia cells, reﬂecting a higher level of inﬂammatory potential at the
epithelial cell surface. (A and B) Supernatants were collected from stool samples from 9 randomly
selected elders from each dementia classiﬁcation group and incubated on T84 epithelial cells for 12 h
prior to relative quantitation of P-gp by ﬂow cytometry (A) or MRP2 by Western blotting (B). (A)
P-glycoprotein expression was induced signiﬁcantly less in samples from elders with Alzheimer’s disease
(AD, yellow) than from those without dementia (none, gray) or with other dementia types (other, blue).
Normalized P-glycoprotein (P-gp) expression is expressed on the y axis. (B) MRP2 did not show a
signiﬁcant difference in expression levels. ***, P 0.05.
Haran et al. ®
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ered all species proﬁled in the elder microbiomes (see Fig. 3B). Comparison mean
squared error (MSE) as a function of the number of generated trees reveals that there
is no difference in MSE between the two models (Fig. 6A), indicating that AD-predicting
taxa are sufﬁcient to predict the microbiome-dependent effect on P-gp function. A
limited subset of taxa signiﬁcantly contribute to the regression in both models and thus
are likely to be major drivers of loss of intestinal homeostasis (Fig. 6B and C). As seen
in our analysis of elder samples, several of the taxa that predict the microbiome-
dependent effect on P-gp function are butyrate-producing organisms, which are higher
in proportion among the no-dementia patients that induce higher P-gp expression. We
then examined the metabolic pathways involved and noted a similar pattern, identi-
fying ﬁve of the butyrate-coding enzyme genes that also signiﬁcantly positively corre-
late with the measured P-gp induction (Fig. S2).
DISCUSSION
Our results advance an understanding of how the intestinal microbiome affects the
gut-brain axis in the context of AD. Species-level differences were explored between
elders with AD, no dementia, and other dementia types and were combined with key
clinical variables including frailty, malnutrition, and medication exposures common
among the elderly and known to inﬂuence the microbiome composition. This study
identiﬁed a dysbiotic pattern seen among AD elders in comparison to those without
dementia or with other dementia types. This pattern is composed of reductions in key
butyrate-producing anti-inﬂammatory species with increases in species known to have
associations with either neurological disorders via inﬂammation or to other colonic
inﬂammatory states.
AD elders were characterized by lower proportions of key butyrate-producing
species, such as members of the Butyrivibrio (B. hungatei and B. proteoclasticus) and
Eubacterium (E. eligens, E. hallii, and E. rectale) genera, as well as species Clostridium sp.
SY8519, R. hominis, and F. prausnitzii. AD elders also had diminished butyrate enzyme-
encoding genes than did elders without dementia. Butyrate is an essential metabolite
in the human colon. It is the preferred energy source for the colonic epithelial cells, and
it contributes to the gut barrier maintenance; also, it has both immunomodulatory
and anti-inﬂammatory properties (39). We infer that lower proportions of butyrate-
producing species would lead to a proinﬂammatory colonic epithelial state.
Elders with AD had increased proportions of bacterial species identiﬁed in our
analysis that have previously been shown to associate with AD. These include O.
FIG 6 Dysbiotic microbiome species from elders with Alzheimer’s disease can accurately predict in vitro P-glycoprotein expression levels. Random forest
regression analysis was performed to predict P-glycoprotein expression as a function of the bacterial relative abundances obtained from whole-genome
sequencing of elders with Alzheimer’s disease and without any dementia. (A) A side-by-side comparison of the two models’ mean squared error (MSE) as a
function of the number of generated trees demonstrates no difference between the MSE of the model obtained by training using only the top 30 features
discriminating AD and no dementia (see Fig. 3, green line) and a model obtained by using information of all the available species (purple lines). The regression
was performed in both cases starting from 500 different initial random seeds. (B) Variables with positive importance (and hence signiﬁcantly contributing to
the regression) resulted to be only a limited subset of taxa that differentiate Alzheimer’s disease from no-dementia individuals. (C) Species selected by the
regression model are predicted to either induce or repress P-glycoprotein expression levels. Observations are colored according to dementia status (AD, red;
no, blue).
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splanchnicus, a bacterial species with genes that have been associated with the Alzhei-
mer’s pathway (25) and the relative abundance of Odoribacter spp. that has been shown
to be increased in transgenic AD mice (40). Additionally, O. splanchnicus has also been
previously linked to other neurological disorders, speciﬁcally autism (41). The human
pathogens K. pneumoniae, B. fragilis, and E. lenta all have previous known associations
to AD and were seen in increased relative abundances in our AD elders. Klebsiella spp.
are commensal bacteria capable of assembling extracellular amyloids, the release of
which can induce cytotoxicity similar to pathological A in AD patients (42). B. fragilis
has known AD associations through its production of lipopolysaccharide (43), and E.
lenta is a signiﬁcant human pathogen that is often associated with serious gastric
pathology (44). Our model also robustly identiﬁed a representative species of the
sulfate-reducing Desulfovibrio genus (D. fairﬁeldensis) to be a high-importance predictor
that is enriched in the AD cohort. An increased proportion of sulfate-reducing bacteria
has been observed in multiple dysbiotic and colitogenic states (45, 46). Other species
with decreased proportions have been seen in other diseases, such as F. prausnitzii with
Parkinson’s disease (47) and R. hominis in patients with Crohn’s disease and ulcerative
colitis (48, 49).
Uniquely, our study goes on to demonstrate that stool samples from elders with AD
can induce lower P-gp expression levels than seen with samples from elders with either
no dementia or other types of dementia. A loss of P-gp expression or a reduction in its
function correlates with inﬂammation in the gastrointestinal tract in mice and humans
(9). Reciprocally, clinical evidence indicates that the MRP2 pathway is activated in
chronic intestinal inﬂammation (36). In fact, we are able to demonstrate that the taxa
that differentiate the AD microbiome of elders from those without dementia can also
predict P-gp expression levels in both of these groups. The top species identiﬁed here
in predicting P-gp expression include, once again, key butyrate producers, such as
members of the Eubacterium, Clostridium, and Butyrivibrio genera, as well as key
butyrate-encoding enzyme pathways. Other species, such as Bacteroides dorei and
Akkermansia glycaniphila, have been associated with gut inﬂammation and autoim-
mune diabetes (28), and Adlercreutzia equolifaciens, a beneﬁcial microbiota member
known to reduce epithelium inﬂammation (30, 31). Taken together, the microbial taxon
members found to best predict the observed P-gp expression are all known to
inﬂuence colonic inﬂammation in other pathological states.
In summary, we demonstrate that the microbiome patterns among elders with AD
are similar, represented by lower relative abundances of butyrate-producing species
and higher relative abundances of taxa known to cause proinﬂammatory states com-
pared to those with either no dementia or other dementia types. Importantly, this work
is an important advance to bridge previous microbiome association studies with AD
toward causality by showing how the AD microbiome observed can potentially ad-
versely affect intestinal epithelial homeostasis via dysregulation of the P-gp pathway.
Our study supports the conclusion that the relationship between the intestinal micro-
biome and an altered epithelial homeostasis is a means by which the microbiome
impacts this devastating neurodegenerative disorder.
MATERIALS AND METHODS
Study setting and population. This prospective cohort study was approved by the institutional
review board at the University of Massachusetts Medical School. This cohort is of NH elders 65 years of
age who lived in one of four NH facilities located in central Massachusetts. We approached elders across
all sites who had been living at that facility for 1 month and did not have any diarrheal illness or
antimicrobial exposure within the preceding 4 weeks. No elders suffered from dysphagia or had a
feeding tube. Any elders with antimicrobial exposure or a diarrheal illness during the conduct of the
study were excluded from this analysis.
Data collection. We conducted baseline and end-of-study medical record abstraction for factors
associated with key study outcomes. These factors included, but were not limited to, age, nutritional
status, comorbidities, use of proton pump inhibitors, and frailty (50). Determination of the diagnosis of
Alzheimer’s disease dementia or other dementia was made by querying the facility medical record and
conﬁrmed by the facility treating physician. Dementia severity was determined by the study staff using
the clinical dementia rating (CDR) scoring system. The CDR is a widely used semiobjective instrument for
staging dementia severity (51, 52) that has been previously used in reporting gut-brain axis associations
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among Alzheimer’s disease patients (4). Elders with a CDR score of 0 or 0.5 were categorized as no
dementia, 1 as mild dementia, and 2 or 3 as moderate/severe dementia. We obtained age, sex, and
medical history from the NH record. Both daily and as-needed medications were obtained from the
facility’s medical record. Polypharmacy was deﬁned using the most commonly reported deﬁnition of ﬁve
or more daily medications (53). Polypharmacy has been shown to represent a determinant of gut
microbiota composition independent of speciﬁc drug classes and has detrimental clinical consequences
(54). We categorized elders based off the continuous age variable into 4 age categories for analysis, as
follows: category 1, 65 to 74 years; category 2, 75 to 84 years; category 3, 85 to 94 years; and category
4, 95 years of age. Frailty was categorized according to the validated and widely utilized Canadian
Study of Health and Aging’s (CSHA) 7-point Clinical Frailty Scale (55). This has been previously validated
in demonstrating signatures of frailty in the gut microbiota (19, 56, 57). We assessed nutritional status
using the Mini Nutritional Assessment (MNA) tool (58–60). Elders were categorized as normal, at risk, or
malnourished based on the MNA survey administered to the elders by trained research staff or the nurse
caring for the elder if mentally impaired. All elders were enrolled for a total of 5 months in which we
monitored for any changes to their care.
Sample collection and processing. We collected stool samples longitudinally once a month for up
to 4 months from each elder. DNA was extracted from samples using the PowerMag soil DNA isolation
kit on an epMotion 5075 TMX liquid handling workstation, according to manufacturer protocols (Mo Bio
Laboratories catalog no. 27100-4-EP). Sequencing libraries were constructed using the Nextera XT DNA
library prep kit (Illumina, Inc. catalog no. FC-131-1096) and sequenced on a NextSeq 500 sequencing
system as 2 150-bp paired-end reads.
Sequence processing and analysis. Shotgun metagenomic reads were ﬁrst trimmed and ﬁltered of
host contamination using Trimmomatic (61) and Bowtie2 (62) as part of the KneadData pipeline
(https://bitbucket.org/biobakery/kneaddata). Reads were then proﬁled for microbial species relative
abundances by mapping them to a NCBI bacterial genomes k-mer database with Kraken (17) and by
reconstructing the resulting relative abundance proﬁle at the species level with Bracken (18). Normalized
taxonomic abundances were then used for downstream statistical analysis in R (see below). To determine
the abundance of enzymes coding for butyrate production, we mapped host-decontaminated shotgun
metagenomic reads to a database of butyrate reference protein sequences (63) using ShortBRED (64).
Data analysis. We performed t-distributed stochastic neighbor embedding to ﬁrst determine
sample similarity with respect to dementia conditions. Permutational multivariate analysis of variance
(PERMANOVA) was performed to evaluate inter- versus intraindividual variability in bacterial proportion.
To determine genera with signiﬁcant differences among groups, we used a beta-regression model with
zero inﬂation to predict genus proportion as a function of clinical covariates, including age, frailty,
malnutrition score, medications, and dementia state (no/other/AD). To account for the repeated sam-
pling nature, we used generalized linear mixed models using the R package glmmTMB. We reported in
our analysis genera with a P value associated with the dementia state smaller than 0.05.
For the random forest classiﬁcation according to dementia status, we selected at random one sample
per individual and built 3,000 decision trees. This operation was repeated 30 times and using 100
different random seeds. Bacteria were ranked based on the associated mean decreased accuracy
distribution across the 30 trials. Bacteria that were ranked in the top 30 important in at least 90% of the
100 seed iterations were considered discriminatory. For the butyrate enzyme differential abundance
analysis, we used linear-mixed effect modeling with elder identiﬁcation (ID) as a random effect.
Spearman’s correlation was used to correlate the abundance of butyrate enzymes with P-gp expression.
Cell culture. T84 intestinal epithelial cells at passages 50 to 79 (ATCC) were grown in a 1:1 mixture
of Dulbecco’s modiﬁed Eagle’s medium (DMEM) and Ham’s F-12 nutrient mixture (Thermo Fisher
Scientiﬁc) supplemented with 14 mM NaHCO3, 15 mM HEPES buffer (pH 7.5), 100 units/ml penicillin-
streptomycin, and 5% heat-inactivated fetal bovine serum (FBS). Cells were maintained at 37°C and 5%
CO2. Monolayers were grown on collagen-coated tissue culture-treated 6-well plates (Costar) and used
6 to 8 days after plating. Prior to incubation with fecal supernatants, cells were serum starved for 1 h in
serum-free T84 growth medium.
Fecal supernatant preparation. Human fecal supernatants were prepared as previously described
(65, 66). Fecal samples freshly voided and stored at80°C were weighed and resuspended in serum-free
growth medium to 0.25 g/ml (wt/vol). Samples were homogenized with gentle vortexing and manual
grounding with a sterile pipet tip, followed by centrifugation at 10,000 g for 15 min. The supernatant
was sterile-ﬁltered through a 0.22-m polyethersulfone (PES) ﬁlter and diluted 10-fold in serum-free T84
growth medium before adding to the surface of T84 monolayers. Cells were incubated with fecal
supernatants for 12 h at 37°C and 5% CO2.
P-glycoprotein detection by ﬂow cytometry. Cells were washed with phosphate-buffered saline
(PBS) and then lifted with 0.25% trypsin-EDTA (Gibco) for 15 min at 37°C. Cells were washed and set to
0.5E6 cells/ml/sample in cold 1 stain buffer (PBS plus 3% FBS plus 1 mM EDTA). Cells were incubated
for 30 min in 100 l stain buffer containing an antigen-presenting cell (APC) anti-human P-gp UIC2 clone
(BioLegend catalog no. 348607), or isotype control APC mouse IgG2a() (BioLegend catalog no. 400221).
Cells were washed and resuspended in 4=,6-diamidino-2-phenylindole (DAPI; Thermo) for live/dead
differentiation. Cell suspensions were ﬁltered through 40-m nylon mesh prior to data collection on a
MACSQuant10 ﬂow cytometer (Miltenyi Biotec). Data were analyzed using the FlowJo software (Tree
Star). The geometric mean of the APC population was computed for each sample and normalized to an
untreated medium control sample.
MRP2 detection by Western blotting. Cell monolayers were lysed in 1 lysis buffer (20 mM Tris [pH
7.5], 120 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 1 protease inhibitor
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cocktail [Roche]). Lysates were centrifuged at 12,000 rpm for 5 min at 4°C. Supernatants were normalized
for protein concentration, separated by SDS-PAGE gels under reducing conditions, and transferred to
nitrocellulose membranes. After 1 h of incubation in PBS-based blocking buffer (Li-Cor), blots were
incubated overnight with primary antibodies anti-MRP2 (catalog no. Ab3373; Abcam) at a 1:100 dilution
or anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH; catalog no. MAB374; Millipore) at a
1:40,000 dilution. After washing with PBST (PBS plus 0.1% Tween), membranes were incubated for 1 h in
the secondary antibody IRDye 800CW goat anti-mouse IgG (Li-Cor) at a 1:5,000 dilution (MRP2) or
1:40,000 dilution (GAPDH). Membranes were scanned using an Odyssey infrared imaging system (Li-Cor).
Densitometry analysis was performed using Image Studio Lite version 5.2. Densitometry values for MRP2
were normalized to internal loading control GAPDH.
To predict in vitro P-gp induction from microbial proportions and test that AD versus no-dementia
discriminatory microbes are responsible for the observed P-gp proﬁling, we built a random forest
regression model. We again used 3,000 trees and 500 different initial random number seeds. The
proportion of bacteria resulting to have positive contribution to the MSE were plotted against the P-gp
levels in the corresponding samples. One sample t test between for the MSE of the model built with
preselecting AD versus no classifying features and a model built using all the microbial taxa were
performed to test the null of no difference in prediction accuracy.
Ethics approval. This prospective cohort study was approved by the institutional review board (IRB)
at the University of Massachusetts Medical School (docket H00010892).
Data availability. The data sets and code will be made available to the scientiﬁc community for
further analysis upon written request to John P. Haran.
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